ScholarIQanswers from OpenAlex

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

PaperCitations, authors & open-access status

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma have?

ScholarIQcitation count

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma has 306 citations in the OpenAlex counts ScholarIQ stores.

When was Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma published?

ScholarIQyear

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma has 2017 year in the ScholarIQ index.

What is the open-access status of Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma?

ScholarIQoa status

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma has gold oa status in the ScholarIQ index.

What is the DOI of Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma?

ScholarIQdoi

The DOI for Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma is on the source record.

What is the PMID of Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma?

ScholarIQpmid

The PMID for Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma is on the source record.

What is the OpenAlex record for Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma?

ScholarIQopenalex

The OpenAlex for Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial